Eli Lilly & Co. (LLY) Tops Q2 EPS by 33c, Raises FY EPS Guidance

Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $1.89, $0.33 better than the analyst estimate of $1.56. Revenue for the quarter came in at $5.5 billion versus the consensus estimate of $5.76 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2020 EPS of $7.20-$7.40, versus the consensus of $6.81. Eli Lilly & Co. sees FY2020 revenue of $23.7-24.2 billion, versus the consensus of $24.01 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• William Blair Downgrades On Holding AG (ONON) to Market Perform
• LB Pharmaceuticals Inc (LBRX) Misses Q2 EPS by 93c
• Achieve Life Sciences (ACHV) Misses Q2 EPS by 64c